Long-Term Outcome of Liver Transplantation in HIV-1-Positive Patients: 15-Year Follow-Up
Table 3
Long-term outcome of patients.
No.
Outcome
Latest HAART
Latest CD4+/µL
Latest CD8+/L µL
Latest HIV-1 PCR copies/mL
Latest HCV RNA (and HVB RNA*) IU/mL
Survival after LT (year)
Postoperative liver biopsy
1
Alive
3TC, ABC, ATV
780
850
<20
0
15.0
Recurrence of hepatitis C (6 y 7 m). Mild nonspecific changing with bridging fibrosis, no rejection, and no hepatitis (10 y 1 m).
2
Deceased Sep’ 00
3TC, d4T, ddI, LPV/r
410
1170
230
0.3
Moderate acute rejection two weeks after LT, RAI = 6 (1 m). Moderate acute rejection with ischemic change (3 m).
3
Alive
3TC, ABC, LPV/r
380
350
<20
−
13.2
Mild acute rejection (RAI = 3-4) (3 m). Suspect early chronic rejection (RAI = 3) (1 y 3 m). Early chronic rejection, toxic change, RAI = 2 (5y). Slight toxic changing. No fibrosis, no rejection, and no hepatitis (10 y 4 m).
4
Alive
3TC, ABC, ZDV
440
610
<20
0
12.6
Ischemic or toxic change (4 m). Recurrence of hepatitis C, fibrosis (1y). Recurrence of hepatitis C. Cirrhotic liver (3 y). Cirrhotic liver, no rejection (5 y).
5-1
Re-LT Nov’ 01,
3TC, d4T, ddI
90
360
<50
1.2
Cholestatic liver, bile duct obstruction with cholangitis, no rejection, no hepatitis (4 m). Cholestatic liver, bile duct obstruction with cholangitis, no rejection, and no hepatitis (6 m).
5-2
Deceased Jul' 02
3TC, d4T, ddI
30
70
<50
0.7
Mild acute rejection without sign of hepatitis (RAI = 3) (1 m). Cholestatic liver with bile duct obstruction or toxic effect and no rejection or hepatitis (2 m). Cholestatic liver without sign of rejection or hepatitis (3 m).
6
Alive
3TC, ABC, RAL
460
580
<20
3.8
Steatosis. Toxic or metabolic effect with acute cholangitis, no rejection, and no hepatitis (2 y). Recurrence of low-grade hepatitis C (3 y).
7
Alive
TDF, FTC, LPV/r
440
1450
<20
3.0
Recurrence of hepatitis C (1 y).
8
Alive
3TC, LPV/r
390
2280
<20
2.0
No rejection and no hepatitis (7 m). Recurrence of hepatitis (1 y).
9
Alive
TDF, FTC, RAL
110
330
<20
0*
1.3
Mild acute rejection (RAI = 4) (0.7 m). Recurrence of hepatitis (1 m). Cholestatic liver, bile duct obstruction and pericholangitis, and recurrence of hepatitis (3 m).
Only for patient 9. Abbreviations: ATV: atazanavir; RAI: rejection activity index; (m): month; (y): year after transplantation.
